Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirogacestat pharmacodynamic study on BCMA in healthy male volunteers
NL-OMON53403Completed
- Sponsor
- SpringWorks Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nirogacestat in multiple myeloma (MM) (4 arms), sponsored by SpringWorks Therapeutics. Primary endpoints: Pharmacodynamic effect of nirogacestat on BCMA and Exposure-response relationship for mbBCMA and sBCMA. Started Apr 2022; status: completed.
02
Drugs
nirogacestat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53403.